Advertisement

Topics

"If All You Have is a Hammer …": Transplants for Myelodysplastic Syndrome (MDS) after Hypomethylating Agents (HMA) Fail.

08:00 EDT 12th July 2017 | BioPortfolio

Summary of ""If All You Have is a Hammer …": Transplants for Myelodysplastic Syndrome (MDS) after Hypomethylating Agents (HMA) Fail."

No Summary Available

Affiliation

Journal Details

This article was published in the following journal.

Name: Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
ISSN: 1523-6536
Pages:

Links

DeepDyve research library

PubMed Articles [8434 Associated PubMed Articles listed on BioPortfolio]

Incorporating novel approaches in the management of MDS beyond conventional hypomethylating agents.

In the last decade, the treatment of higher-risk myelodysplastic syndromes (MDS) has revolved around the azanucleosides, azacitidine and decitabine, which at lower doses are postulated to work predomi...

Benefits of hypomethylating therapy in IPSS lower-risk myelodysplastic syndrome patients: A retrospective multicenter case series study.

We retrospectively analyzed the results of hypomethylating therapy in 586 patients (azacitidine in 423 and decitabine in 163) with International Prognostic Scoring System (IPSS) lower-risk myelodyspla...

Histiocytoid Sweet Syndrome and Myelodysplastic Syndrome-Reply.

Myeloid Sarcoma in a Patient with Myelodysplastic Syndrome Associated with del(5q-): Case Report and Literature Review.

Myeloid sarcoma (MS) is defined in the World Health Organization classification as a tumor mass consisting of myeloblasts with or without maturation and involving any anatomic site other than the bone...

Histiocytoid Sweet Syndrome and Myelodysplastic Syndrome.

Clinical Trials [5182 Associated Clinical Trials listed on BioPortfolio]

Rabbit Anti-thymocyte Globulin in the Treatment of Patients With Low to Intermediate-1 Risk Myelodysplastic Syndrome

This is a Phase II, single-arm, open-label, multinational, multicenter study of rATG in patients with low or intermediate-1 risk MDS who have either failed 1 prior treatment with growth fa...

Trial of Volasertib With or Without Azacitidine in Patients With Myelodysplastic Syndromes

The objectives of this trial are to evaluate the safety, tolerability, maximum tolerated dose (MTD), pharmacokinetics and preliminary efficacy of volasertib in two dosing schedules of intr...

Erlotinib in Hegher Risk Myelodysplastic Syndrome

The aim of this study is to evaluate the therapeutic efficacy of erlotinib in high-risk myelodysplastic syndrome (MDS) patients (with at least 10% of bone marrow blasts) ineligible for or ...

Hypomethylating Properties of Freeze-dried Black Raspberries (BRB) in Patients With Myelodysplastic Syndrome

This is a phase II, single-group pilot study to evaluate efficacy and pharmacokinetics. This study's overarching aim is to evaluate the systemic effects of black raspberries in patients wi...

Determination of Safe and Effective Dose of AMG 531 in Subjects With MDS Receiving Hypomethylating Agents

The purpose of this study is to evaluate the effect of AMG 531 on the incidence of clinically significant thrombocytopenic events (grade 3 or 4 and/or receipt of platelet transfusions) in ...

Medical and Biotech [MESH] Definitions

A condition characterized by a series of interrelated digital symptoms and joint changes of the lesser digits and METATARSOPHALANGEAL JOINTS of the FOOT. The syndrome can include some or all of the following conditions: hammer toe, claw toe, mallet toe, overlapping fifth toe, curly toe, EXOSTOSIS; HYPEROSTOSIS; interdigital heloma, or contracted toe.

A transplantable carcinoma of the rat that originally appeared spontaneously in the mammary gland of a pregnant albino rat, and which now resembles a carcinoma in young transplants and a sarcoma in older transplants. (Stedman, 25th ed)

Clonal myeloid disorders that possess both dysplastic and proliferative features but are not properly classified as either MYELODYSPLASTIC SYNDROMES or MYELOPROLIFERATIVE DISORDERS.

Agents that have a damaging effect on the HEART. Such damage can occur from ALKYLATING AGENTS; FREE RADICALS; or metabolites from OXIDATIVE STRESS and in some cases is countered by CARDIOTONIC AGENTS. Induction of LONG QT SYNDROME or TORSADES DE POINTES has been the reason for viewing some drugs as cardiotoxins.

A potentially fatal syndrome associated primarily with the use of neuroleptic agents (see ANTIPSYCHOTIC AGENTS) which are in turn associated with dopaminergic receptor blockade (see RECEPTORS, DOPAMINE) in the BASAL GANGLIA and HYPOTHALAMUS, and sympathetic dysregulation. Clinical features include diffuse MUSCLE RIGIDITY; TREMOR; high FEVER; diaphoresis; labile blood pressure; cognitive dysfunction; and autonomic disturbances. Serum CPK level elevation and a leukocytosis may also be present. (From Adams et al., Principles of Neurology, 6th ed, p1199; Psychiatr Serv 1998 Sep;49(9):1163-72)

Quick Search
Advertisement
 


DeepDyve research library

Searches Linking to this Article